Berberine's mechanism involves multiple pathways beyond GLP-1, including direct effects on glucose metabolism, gut microbiota modulation, and inflammation reduction
What the conversation covers Unique challenges in type 1 diabetes , why insulin alone has structural limitations The mechanism , how GLP-1 therapies work The evidence in type 1 diabetes , from early studies to ADJUST T1D and tirzepatide Exploration points , what the evidence tends to show on insulin adjustment, monitoring, and nutrition Future directions , triple and quadruple agonists, reimbursement, and paediatric potential Watch or listen Key themes Why insulin alone has structural limitations The episode opens by exploring why insulin alone has structural limitations in type 1 diabetes
Insert the needle at 45 degrees into the subcutaneous tissue overlying the tendon
The notice specifically calls out one of the biggest providers of compounded GLP-1 drugs: Hims & Hers
Energy Expenditure: Semaglutide GLP-1 also activates brown adipose tissue, which burns calories to produce heat, aiding in weight loss through increased energy expenditure